Related Experiment Video
Updated: Feb 2, 2026
Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
Published on: November 9, 2018
Biochemical Markers, Genotype, and Inflammation in Pediatric Inflammatory Bowel Disease: A Danish Population-Based
Farah Ziade1, Christine Rungoe2, Thomas Kallemose3
1Department of Pediatrics, Hvidovre University Hospital, Copenhagen, Denmark.
Insights
Biochemical markers like albumin at diagnosis can predict a severe disease course in pediatric inflammatory bowel disease (IBD). Genotype may also influence inflammation, suggesting personalized treatment approaches for ulcerative colitis and Crohn's disease.
Area of Science:
- Gastroenterology
- Pediatric Medicine
- Clinical Biochemistry
Background:
- Inflammatory bowel disease (IBD) encompasses chronic conditions like ulcerative colitis (UC) and Crohn's disease (CD).
- Characterizing early biochemical markers is crucial for predicting IBD disease trajectory.
- Understanding the influence of genetic variations on inflammatory markers in IBD is an ongoing research area.
Purpose of the Study:
- To identify biochemical markers at diagnosis in pediatric IBD patients.
- To evaluate the predictive utility of these markers for disease course.
- To investigate the association between patient genotype and biochemical markers of inflammation.
Main Methods:
- Analysis of biochemical markers (e.g., albumin, C-reactive protein) and treatment data from a population-based pediatric IBD cohort.
- Genotyping of 52 single nucleotide polymorphisms (SNPs) previously associated with IBD.
- Longitudinal data collection at diagnosis, 30 days, 6 months, and 12 months post-diagnosis.
Main Results:
- Extensive UC disease correlated with higher C-reactive protein, erythrocyte sedimentation rate, and platelet count at diagnosis.
- Low albumin levels at diagnosis were linked to increased risk of surgery and use of immunosuppressants (azathioprine, anti-TNF-alpha) in both UC and CD patients.
- Specific SNPs in TLR-4, Pregnane-x-receptor, and SLCA10 genes showed associations with changes in albumin and hemoglobin levels over time.
Conclusions:
- Albumin is confirmed as a marker for severe disease course in pediatric IBD.
- Genetic factors may play a role in modulating the inflammatory response in IBD patients.
- Further research in larger pediatric cohorts is warranted to validate these genetic associations and their clinical implications.
Background:
Our aim was to characterize the biochemical markers at diagnosis in patients with inflammatory bowel disease (IBD), to assess the utility of these to predict disease course and investigate if genotype influences biochemical markers of inflammation.
Summary:
Patients were included from a population-based pediatric IBD cohort from Eastern Denmark. Data on biochemical markers and medical as well as surgical treatment were registered at diagnosis, 30 days, 6 and 12 months after diagnosis. Fifty-two single nucleotide polymorphisms (SNPs) known to be associated with IBD were selected for genotyping based on previous genetic studies. Key messages: A total of 190 IBD patients (97 ulcerative colitis [UC], 87 Crohn's disease [CD], and 6 IBD unclassified) were included. UC patients with extensive disease had higher C-reactive protein, erythrocyte sedimentation rate, and platelet count at diagnosis compared to UC patients with less extensive disease. No similar differences between disease extent groups were found in CD. Low albumin at diagnosis was associated with an increased risk of surgery in both UC (OR 1.35; 95% CI: 1.05-1.75) and CD patients (OR 1.23; 95% CI: 1.01-1.48) and increased use of azathioprine and anti-tumor necrosis factor alpha use in the total IBD cohort (OR 1.15; 95% CI: 1.04-1.27 and OR 1.19 [1.08-1.34]). One SNP (rs4986791 in the TLR-4 locus) and 2 SNPs (rs6785049 in the Pregnane-x-receptor gene and rs10500264 in the SLCA10 gene) were associated with a change in albumin and hemoglobin over time respectively in our IBD cohort. Our study confirms albumin to be a marker of severe disease course. Furthermore, the patient's genotype possibly affects the inflammatory response. Future studies in larger pediatric cohorts are needed to confirm our findings.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:38Inflammation